Skip to main navigation
Skip to search
Skip to main content
Research Explorer The University of Manchester Home
Home
Profiles
Research units
Research output
Projects
Impacts
Activities
Press/Media
Prizes
Equipment
Datasets
Student theses
Search by expertise, name or affiliation
Are aromatase inhibitors superior to antiestrogens?
Anthony Howell
, Aman Buzdar
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Are aromatase inhibitors superior to antiestrogens?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Adjuvant Therapy
9%
Anastrozole
81%
Antiestrogen
100%
Aromatase Inhibitor
100%
Breast Cancer
27%
Contralateral
9%
Disease Free Survival
9%
Diseases
27%
Estrogen Receptor
9%
Exemestane
27%
Fulvestrant
9%
Intraductal Carcinoma
9%
Letrozole
27%
Metastatic Breast Cancer
9%
Neoadjuvant Therapy
9%
Overall Survival
9%
Placebo
18%
Survival Analysis
9%
Tamoxifen
100%
Pharmacology, Toxicology and Pharmaceutical Science
Anastrozole
81%
Antiestrogen
100%
Aromatase Inhibitor
100%
Breast Cancer
27%
Disease
27%
Disease Free Survival
9%
Estrogen Receptor
9%
Exemestane
27%
Fulvestrant
9%
Intraductal Carcinoma
9%
Letrozole
27%
Metastatic Breast Cancer
9%
Overall Survival
9%
Placebo
18%
Tamoxifen
100%
Agricultural and Biological Sciences
Anastrozole
81%
Antiestrogen
100%
Aromatase Inhibitor
100%
Estrogen Receptor
9%
Exemestane
27%
Fulvestrant
9%
Letrozole
27%
Placebo
18%
Tamoxifen
100%
Nursing and Health Professions
Antiestrogen
100%
Exemestane
27%
Letrozole
27%
Neoadjuvant Therapy
9%